Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced the initiation of patient enrollment in the phase II HELIX-2 clinical trial evaluating an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE